Clinical Trials Logo

Primary Adrenal Insufficiency clinical trials

View clinical trials related to Primary Adrenal Insufficiency.

Filter by:
  • None
  • Page 1

NCT ID: NCT06299020 Not yet recruiting - Clinical trials for Intermittent Fasting

Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency

Start date: March 4, 2024
Phase: N/A
Study type: Interventional

In primary adrenal insufficiency, there is an increased risk of hypoglycaemia and dehydration. These risks have been little studied particularly during intermittent fasting. The present study aimed to assess these risks in a prospective study of 30 subjects with primary adrenal insufficiency. Patients will undergo a clinical examination, blood sampling and continuous glucose monitoring for fourteen days (one week of fasting and one week of non-fasting).

NCT ID: NCT05222152 Completed - Clinical trials for Primary Adrenal Insufficiency

Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency

CHAMPAIN
Start date: November 23, 2021
Phase: Phase 2
Study type: Interventional

This study is a double-blind, double-dummy, two-way cross-over, randomised, Phase II study to be conducted at approximately 6 investigational sites in 2 countries. The study will compare the efficacy, safety and tolerability of twice daily Chronocort, a modified-release hydrocortisone, with once daily Plenadren, a modified-release hydrocortisone, over a treatment period of up to 2 months in participants aged 18 years and over, diagnosed with primary Adrenal Insufficiency (AI).

NCT ID: NCT03793114 Active, not recruiting - Clinical trials for Primary Adrenal Insufficiency

Screening and Stimulation Testing for Residual Secretion of Adrenal Steroid Hormones in Autoimmune Addison's Disease

Start date: September 26, 2018
Phase: N/A
Study type: Interventional

In autoimmune adrenal insufficiency, or Addison's disease (AD), the immune system attacks the adrenal cortex. As a result, the adrenal cells producing hormones such as cortisol and aldosterone are destroyed, leaving the body with insufficient levels to meet its needs. The common perception is that upon diagnosis of Addison's disease, basically all adrenal hormone production has ceased. There have, however, been found a few individuals who preserve some residual secretion of cortisol even years after diagnosis. The objectives of this study is to find out how common it is, and to explore if residual function have impact on patient outcome. That is, do patients with and without residual function differ when it comes to quality of life, working ability, medication dosages, and risk of adrenal crisis?

NCT ID: NCT02277587 Completed - Clinical trials for Primary Adrenal Insufficiency

Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)

DREAM
Start date: March 2014
Phase: Phase 4
Study type: Interventional

This is a randomized, controlled, open, three-armed, multi-centre study designed to compare the effects of dual-release hydrocortisone preparations versus conventional glucocorticoid therapy on anthropometric parameters, metabolic syndrome, infectious, immunological profile, cardiovascular system, bone mass and quality of life in patients affected by primary or secondary adrenal insufficiency.

NCT ID: NCT01450930 Completed - Clinical trials for Primary Adrenal Insufficiency

Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency

PHYSCA
Start date: November 2011
Phase: Phase 2
Study type: Interventional

Patients with chronic adrenal insufficiency need to adapt their hydrocortisone replacement dose in conditions of physical or psychological stress to prevent life threatening adrenal crisis. In cases of more severe impairment or unsecure gastrointestinal absorption (e.g. gastroenteritis, severe infectious disease), parenteral administration of the hydrocortisone dose is crucial. The study is conducted to offer patients the possibility to perform hydrocortisone self administration in emergency situations in a way of administration which is easy to perform and accepted by the patient. Therefore, pharmacokinetics and safety of subcutaneous hydrocortisone administration will be studied and compared to intramuscular administration.